• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Analysis: DCTs Are Proving Their Benefits, Significantly Cutting Down Trial Costs

Analysis: DCTs Are Proving Their Benefits, Significantly Cutting Down Trial Costs

January 24, 2022

Decentralized trials (DCTs) can provide up to 14 times return on investment for phase 3 trials due to accelerating trial timelines, a new Tufts study has found.

In phase 2 trials, DCTs typically saved one to three months’ worth of time and delivered a net benefit up to five times greater than investment costs.

“On average, the financial returns to drug sponsors from shorter development times, lower clinical trial screen failure rates and fewer clinical trial protocol amendments associated with DCTs substantially exceeded the costs of investing in DCT technologies,” said Joseph DiMasi, director of economic analysis at Tufts’ Center for the Study of Drug Development (CSDD).

The study analyzed data from more than 150 DCTs on the Medable platform using an expected net present value based on trial cycle time, cost and performance benchmarks, in addition to some conservative assumptions about the impact of DCTs and their investment costs.

CSDD has declined to release detailed data from the study prior to it undergoing peer review. When peer review is complete, Tufts will share detailed findings on the financial savings DCTs can provide.

 

To view more CenterWatch Weekly stories, click here.

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing